Table 1_Comparative clinical features and outcomes of invasive pulmonary aspergillosis fol

127 patient records from a single-center retrospective cohort study in China, comparing 45 patients with influenza-associated pulmonary aspergillosis (IAPA) and 82 with COVID-19-associated pulmonary aspergillosis (CAPA). The study, authored by Renwen Zhang and last updated in April 2026, analyzed demographics, clinical features, management, and mortality between December 2022 and September 2024.

Use Cases

• Compare mortality risk and survival curves between IAPA and CAPA patient groups based on the reported hazard ratio.
• Analyze the association between corticosteroid use and severe lymphopenia with patient outcomes as described in the results.
• Investigate the timing of IPA detection relative to viral diagnosis using the reported median time differences.
• Study the prevalence and impact of bacterial respiratory co-infections in the context of viral-associated aspergillosis.

Strengths

• Direct comparison of 45 IAPA and 82 CAPA patients from the same study period and center.
• Analysis includes specific immunological markers (CD4+, CD8+ T cells, B cells) and adjusted mortality risk (HR=4.92).
• Study period is explicitly defined from December 2022 to September 2024.

Limitations

• Row and column counts are unknown, limiting assessment of dataset scale and feature richness.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single center in China, which may limit generalizability to other populations.

Provenance

Source

figshare, authored by Renwen Zhang.

Collection Method

Single-center retrospective cohort study.

Time Range

December 1, 2022 to September 1, 2024.

Freshness

Last updated 2026-04-24 05:39:50; freshness should be verified.

Geography

China (single-center study).